University of Washington: Leukemia trials

The registry lists 20 Leukemia studies with University of Washington as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 5Phase 2 10No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT03023046Phase 2Results posted
• Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid NeoplasmCompletedNCT03012672Phase 2Results posted
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT02767934Phase 2Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT02551718Not applicableResults posted
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative NeoplasmCompletedNCT02121418Not applicableResults posted
• Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicableResults posted
• Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01807091Not applicableResults posted
• Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative NeoplasmCompletedNCT01101880Phase 2Results posted
• Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual DiseaseTerminatedNCT00863434Phase 2Results posted
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00602225Phase 1/2Results posted
• Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04852822
• Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsTerminatedNCT04196010Phase 1
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
• Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid LeukemiaTerminatedNCT03806192Not applicable
• Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
• Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their ChildrenCompletedNCT02129049Not applicable
• Interleukin-2 in Treating Patients With Myelodysplastic SyndromeCompletedNCT00002746Phase 1